Ecolab Q3 2023 Earnings Call Transcript

Quartr
Provided by Quartr
October 31, 2023

There are 13 speakers on the call.

Operator

Greetings. Welcome to Ecolab Third Quarter 2023 Earnings Release Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded.

Operator

It is now my pleasure to introduce your host, Andy Hedberg, Vice President, Investor Relations for Ecolab. Thank you, Mr. Hedberg. You may begin.

Speaker 1

Thank you, and hello, everyone, and welcome to Ecolab's 3rd quarter conference call. With me today are Christophe Beck, Ecolab's Chairman and CEO and Scott Kirkland, our CFO. A discussion of our results, along with our earnings release and the slides referencing the quarter results Are available on Ecolab's website atecolab.com/investor. Please take a moment to read the cautionary statements in these materials, which state that this teleconference and the associated supplemental materials include estimates of future performance. These are forward looking statements and actual results could differ materially from those projected.

Speaker 1

Factors that could cause actual results to differ are described in the Risk Factors section and our most recent Form 10 ks and our posted materials. We also refer you to supplemental diluted earnings per share information in the release. With that, I'd like to turn the call over to Christophe Beck for his comments.

Speaker 2

Thank you so much, Andy, and welcome to everyone on the call. Building on our momentum with strong and reliable growth, that's the headline for Ecolab 3rd quarter. Thanks to exceptional execution by our team. Ecolab delivered a very strong quarter as our momentum continued with 7% organic sales growth, which was actually exactly as expected, an 18% growth in adjusted earnings per share, reaching the high end of our expected range. Against unpredictable macro conditions, we drove continued strong pricing, new business, accelerated volume trends and continued robust margin expansion.

Speaker 2

Our focus remains on our fence, which we are best at, continuing to fuel strong and consistent double digit earnings per share growth. We maintained strong organic sales growth with pricing increasing by 7%. This increase reflects Both the value based pricing we put in place last year and the new pricing we've implemented this year, reflecting the enhanced value we offer to our customers. Our volume trends continue to strengthen as well, which is great news, With new business helping to accelerate volumes despite softening in global end market demand. Organic operating income margin continued its expansion, up 160 basis points compared to last year, reaching 15.5%.

Speaker 2

This notable progress reinforces our path Towards achieving our long term margin goal of 20%. In the 3rd quarter, our adjusted gross margin expanded 360 basis points to 41.3%. This strong expansion is a result of our value based pricing strategy, improved volume trends and a slight decline in delivered product cost. While global energy prices remain dynamic, we're confident in our value based pricing strategy and If absolutely necessary, our capability to implement energy surcharges. We continue to take a prudent stance On the trajectory of delivered product costs, as costs remain up nearly 40% compared to pre inflation levels.

Speaker 2

Assuming the current high energy price environment persists and our cost is only slightly in 2024, We continue to expect very strong gross margin expansion in the quarters ahead. This will help us make progress in achieving our 44% gross margin and our 20% OIF margin target over the next few years. Underlying productivity also remains strong as we continue to leverage our leading digital capabilities. As expected, SG and A expense was relatively stable versus 2nd quarter levels. The year over year comparison reflects the rebuild of incentive based compensation, A result of our strong sales and earnings growth and the strategic investments in our growth engines.

Speaker 2

We also SG and A dollars in Q4 to remain very consistent with second and third quarter levels. Our performance further strengthened across our businesses. The highlight was institutional and specialty, which grew organic sales double digits And organic operating income 28%. Organic OI margin was up 260 basis points to 19.3%, approaching its historical 20% level. Our Industrial segment also performed well, especially comparing to an extremely strong Q3 last year, Led by attractive growth in food and beverage and in water as our unique ability to bring end to end water and hygiene technologies to customers Continues to drive strong share gains in the segment.

Speaker 2

Operating income growth eased a bit in the 3rd quarter, reflecting the incentive based compensation rebuilds as mentioned in the last call. And importantly, we expect this segment's operating income to return to double digit growth in Q4. Our healthcare bifurcation strategy is progressing well. Strong pricing and new business had to improve underlying sales growth and operating income. The business also benefited from larger than normal surgical sales, which is not expected to recur.

Speaker 2

While we are pleased with our progress, Delivering sustainable and profitable growth remains a focus for me and for our team. Life Sciences growth also improved to mid single digits But continued short term pressure for everyone in this market as our team continued to win share. While we expect the market to remain under pressure for the next few quarters, Our ongoing investments in additional new product capacity and team capabilities will allow us to capitalize on attractive long term high growth, High margin opportunities. In summary, in the Q3, we delivered as expected with strong sales and solid earnings growth. Now looking ahead, we expect our strong performance to continue in the 4th quarter with adjusted earnings per share increasing 17% to 24% versus last year, Which is above the mid teens growth we had guided to during our Q2 call and will bring the full year EPS north of 20 nineteen's EPS.

Speaker 2

This performance is expected to be driven by new pricing, volume growth and robust gross margin expansion expected to be up 250 basis points to 300 basis points versus last year. As we shared with you at our Investor Day in September, We see continued strong momentum in 2024. Even as global uncertainty remains with softening macro demand, we continue to expect mid teens of better Growth in adjusted earnings per share in 2024. As always, we remain good stewards of capital by continuing to invest in the business, Increasing our dividend, reducing leverage and returning cash to shareholders. Most importantly, with the best team, Science and capabilities in the industry, we will continue to grow our share of the stable and high quality $152,000,000,000 market we serve.

Speaker 2

I believe that Ecolab's long term fundamentals are stronger than ever, and I am confident in our outlook for continued strong performance as we work to deliver superior shareholder returns. So thank you for your continued support and your investment in Ecola. I look forward to your questions.

Operator

We'll now be conducting a question and answer session. One moment please while we poll for questions. Thank you. Thank you. Our first question comes from the line of Tim Mulrooney with William Blair.

Operator

Please proceed with your question.

Speaker 3

Christophe, Scott, good afternoon.

Speaker 2

Good afternoon, Tim. So I

Speaker 3

see you clipped 19% OI margin in institutional in the 3rd quarter, which was great to see. If you go back to pre pandemic times, you're doing about 21% OI margin every year on an annual basis. I think there's some debate amongst the investor community about whether or not Ecolab will ever get back to that 21% OI margin days or If the business has structurally changed, I'd love to get your perspective on that Christophe, how long that might take, particularly given the good momentum that we've seen this quarter?

Speaker 2

Thank you, Tim. I have no doubt in my mind that we will get there. We have a great team running a great business on a great trajectory. And as mentioned many times, Tim, the P and L of INS will end up in a better place So in Q4, as mentioned during Investor Day as well, our OI dollar will already be back to the 2019 level. So I really expect to cross that 20%, 21% line in the next few years, while we drive new business, Innovation, price, the advantage of the new organization as well with the focus on sales and service And leverage as well digital technology as we've done over the past few years.

Speaker 2

So of all the opportunities we have in front of us, all the challenges that we might be facing, I think institutional is going to be probably one of the best promises that we have ahead of us.

Operator

Our next question comes from the line of Seth Weber with Wells Fargo. Please proceed with your question.

Speaker 4

Hi, thanks. Good morning. You mentioned a few times in the slides, in the release, in your comments just about new business wins. I'm just can you talk The selling environment, your sort of traction with new wins and how we should think about New adds going forward. Thank you.

Speaker 2

Thank you, Seth. Well, selling new business is what we best add and what we like the most Doing so, our shift to offense, over the past few quarters is delivering results, Because our team is really focused on driving new business with our customers, in more difficult environment and it's always been the case At Ecolab, well, our customers are looking for ways to improve their operating performance, which is what we've always done for them and that they need the most right now. So they're very receptive to what we can do as well for them. At the same time, We're bringing as well all the offerings from the company, especially Water and Hygiene in Industrial segments, but also in institutional, which are very well received by our customers. And we have innovation As well, we just made a step change over the last few years, which are addressing Customer challenges or opportunities that they have.

Speaker 2

So all in, the team focused on what they truly like with the right tools, right innovation, right new products and customers that are open to what we can do for them speak improving their operating performance. Ultimately, that's all driving better

Operator

Our next question comes from the line of Josh Spector with UBS. Please proceed with your question.

Speaker 5

Yes. Hey, Christophe. I had a question along the similar lines, and particularly just related with Just volume expectations, I mean, you were pretty confident a couple of months ago that you were going to deliver positive volumes in 3Q. I guess it rounds down to 0 or maybe Flat ish is the best way to describe how that came in. You're talking about positive volumes in the 4th quarter.

Speaker 5

I guess, I don't know, did 3Q change versus your expectations of where it would come in? And the backlog combined of where it would come in and the backlog combined with or the new wins combined with base earnings, I guess, how do you envision volume moving into early next Thanks.

Speaker 2

Yes. Volume is the most important driver obviously for us. And Q3 happened Pretty much as expected. We can talk about rounding, obviously here, but we were in positive territory, which is good. And if we exclude Europe, Which is the most difficult place in terms of volume.

Speaker 2

We are at plus 1% already and I feel Confident that in Q4, we will have a 1% volume growth overall, so for the company. So when I look at the Trajectory that we're having on volume, especially with all the pricing that we've done, over the past few years and in a market that's not exactly booming right now, I feel really good with what we're doing, where we're heading. And to your point, so for 2024, while it's the best way we can close the year, it's with Good volume momentum in order to start 2024 in whatever environment we're going to find with a company that's having good sales momentum, which

Operator

Our next question is from the line of Mike Harrison with Seaport Research Partners. Please proceed with your question.

Speaker 6

Hi. Congratulations on Nice quarter here. Just in terms of the Healthcare and Life Sciences business, I'm curious if we saw Any of the benefits from some of the changes that you're making on the healthcare side of that business already in Q3 Or are those actions still to come? And then just curious on the one time 6% sales benefit, Did that also help margins come in higher or was that kind of an average incremental margin contribution?

Speaker 2

Thank you for your nice comment, Mike. Three comments on your question. So focused on health Not life science. I know that they all combine, obviously, but 2 very different stories, as we know. So first, if We saw some results of the organizational changes in Q3.

Speaker 2

The short answer is yes, but it's early. I've been really impressed With how the team has executed this bifurcation, truly leveraging the market strength, the breadth, The critical mass of institutional, both in terms of selling to new customers or existing institutional customers to healthcare portfolio and at the same time, Getting the costs down, the team has moved very fast, very well and I'm really pleased with where we are right now. But that being said, it's very early in the process. So it's going to leverage as well or lead to better results in the quarters to come. There's still a lot of work that remains, but I like the progression.

Speaker 2

It's going to be always better as we move forward. Now the last point on the one time sale was related to a contractual commitment That we had to deliver, so by the end of Q3, if you strip that out, healthcare had kind of No single type of growth, which is better than in the past, but probably what we're going to see saw in the next immediate quarters until We can truly accelerate by leveraging the power of institution. But overall, I like the progress that we're making on healthcare, But let me be very clear. So I've not been happy, so with the performance of healthcare for many years, I'm really happy with what the team is doing now in terms of transformation, Earlier results, more is to come and more work is also required to get to the place that we all want to be with that business.

Operator

The next question is from the line of David Begleiter with Deutsche Bank. Please proceed with your question.

Speaker 7

Thank you, and a very nice quarter, Christophe and team.

Speaker 2

Thank you, David.

Speaker 7

Just on the delivered product costs, they came in below your expectations or better than your expectations. What drove that? And what are your expectations for Q4?

Speaker 2

So DPC, your delivered product cost was roughly 3% down versus last year, A little bit better than what we had expected. It's always a very broad mixed bag as you know. So we have 10,000 raw materials that we buy. So they didn't all go in the same direction, obviously. So Some easing on the market.

Speaker 2

At the same time, our supply chain team speak, procurement team Did also some remarkable work as well with our partners' suppliers. So brought both together led to this 3 Since easing versus last year, keeping in mind that our costs are still 40% higher than where they used to be Pre inflation, that's important to keep in mind. I expect kind of the same type of costs for Q4, so kind of a similar Easing versus the prior year and I expect basically so those costs to stay similar In the quarters to come, which will mean, so the slight easing versus 2023 when we talk about 2024. So I'm not banking on big improvement in the quarters to come. And if they come, well, we will all benefit from them.

Speaker 5

Thank you.

Operator

The next question is from the line of Jeff Zekauskas with JPMorgan. Please proceed with your question.

Speaker 8

Thanks very much. Ecolab buys its raw materials sometimes monthly, sometimes quarterly, Sometimes annually. So raw materials have moved down through the course of the year, but it may be that the timing Of your contractual agreements has slowed the benefits for Ecolab. Can you talk about how you purchase your raw materials in terms of the way raw materials are repriced? That is, should we expect different incremental changes on a 6 month basis or a 3 month basis or an annual basis.

Speaker 2

Well, I have two ways to answer your question. So in a complicated way or in a simple way, Jeff. So I'll go for the simple way. You're right that depending on the raw materials, it's monthly, some quarterly, some annually, with different types Of contractual agreements, I think we have a very good team. We have the new leadership as well who is doing an Exceptional work, by the way, so on procurement.

Speaker 2

The short way, to explain it is usually we have a 2 or 3 quarters lag between sort of the market to market price changes up or down, By the way, that impact 2 or 3 quarters down the road, our P and L. That's the rule of thumb that I'm using And that you should be using as well.

Operator

Our next question is from the line of John McNulty with BMO Capital Markets. Please proceed with your question.

Speaker 9

Yes. Thanks for taking my question. So the industrial business, I guess I was a little surprised to not see A little bit better margin lift just given that you have gotten some good pricing there and the raw materials does look like are starting to come off. So I guess can One, can you help us to think about what the volumes were there? And then do you feel like we're at a bottom in terms of the volumes for that business And maybe we start to see things level off a bit or is there more to kind of think about in terms of concerns going forward?

Speaker 9

How would you frame that?

Speaker 2

Thank you, John. Well, industrial is in a very good place, actually. But I'd like to ask Scott maybe so to give some perspective on our margins evolution.

Speaker 7

Yes, happy to Christophe. So, yes, as you're referring to the industrial OI growth was at 8%. But the growth rates are really impacted by a couple of things. Certainly, there's a base comparison to last year. If you look at this on a 2 year basis, That business is improving.

Speaker 7

And then also, as we spoke to on the SG and A, they're impacted by the incentive comp given the strong performance they've had in the year. But overall in that business, as Christophe sort of referenced that the strong pricing that we delivered this year, we continue to add new pricing. And now as we start to see that DPC Easing modestly, and they were certainly the biggest impacted by that. But on a dollar basis, that OI really remains very strong and think we'll continue to improve off these levels. But Really, as Christophe mentioned in the opening, expect that the growth to return to double digit, OI growth in the Q4, and you'll see the marginal impact on that as well.

Speaker 2

Yes. As mentioned early on, John, I like a lot the performance of industrial for the past few years and that's going to be even more true in the years to come. If you strip out that incentive based compensation, so the OI growth would be in the upper teens, which is what you're going to see in the Q4 as well. So it was kind of a 1 quarter story, underlying performance very strong.

Operator

Our next question comes from the line of Manav Patnaik with Barclays. Please proceed with your question.

Speaker 10

Thank you. Just a 2 parter, Christophe. So in the pricing, firstly, I think in terms of What you already have in place, if you roll through, I think you get mid single digit pricing next year. But just curious on how you feel like you could keep Pushing the pricing dynamic. And then just a quick follow-up was the new sales pipeline that you're really confident on, like How big is that perspective?

Speaker 10

Like how much of a volume headwind can that offset?

Speaker 2

Great question, Manav. Sorry, they're related obviously. But the first one, pricing dynamics. If we think about our pricing, so going up, retention has remained very stable, customer And at the same time, so volume accelerating. So he's basically showing that, our Balance of pricing and volume acceleration is going quite well.

Speaker 2

And I'm keeping a very close eye On that, because we're keeping customers for life in our company, and I want to make absolutely sure we do that the right way for So bottom line, I like the pricing that we've had so far when I look at What's going to happen in the next few quarters? So in Q4, the carryover from last year by definition is Going to get close to 0, obviously, since it's going to be annualizing. So over the 12 months, new pricing is quite good Actually, so I'm especially pleased with the new pricing we have, which we will have, obviously in Q4. And in 2024, it's a bit early, so to go too much in details, but we're going to be pleased with the pricing that we have while we keep accelerating, as well as the volumes are really keeping both, in a very good place. Now to your question, on the net new business, As you know, so we're not reporting, the dollar value of the growth, but we are really still reaching record levels On a quarterly and annual basis, as well of new business, our team is 80% focused on new business.

Speaker 2

It's where we're good at, what we like doing, as mentioned before. And those good results ultimately are compensating for the Softening of the demand globally out there from all our customers. So if our volume is accelerating, it's all related to our new business.

Operator

The next question is from the line of Shlomo Rosenbaum with Stifel. Please proceed with your question.

Speaker 11

Hi, good afternoon. Thank you for taking my question. Hey, Christophe, I want to get back to a question that was asked earlier in terms of the volume. It sounds like after 3 quarters of negative volumes, You're starting to get into the positive territory. Could you just go into some of the Kind of standout categories over there, what volumes are increasing and which volumes are decreasing?

Speaker 11

I know you mentioned a little bit Geography, but maybe you could talk a little bit just by like business unit, what's going on in various areas of industrial. Obviously, paper is down, but what are the standout areas where you might have accelerating volumes versus the ones which are shrinking? And how we should think of that going into next year with some of the softening end markets?

Speaker 2

Yes. So to give you a simple answer, so the ones that are on the soft side, paper, you mentioned it and Europe Here's the second one. So those are the 2. Everything else is trending in either positive direction or improved direction If they were on the negative side, I'm especially pleased with the INS, the institutional specialty improvements And water is going to keep improving as well. So those 2 key businesses are going to be good in the quarters to come at least with What we're seeing as well right now.

Speaker 2

So we have passed elimination as well, which is always a bit of a different volume Play, as we know, that's doing exceptionally well. We know that competition has a lot to do with themselves, By the way, it's providing us an opening for us to gain share as well and our team is doing an excellent job In pest elimination, where we see saw growth, really steady, strong and margins as well at the same time, so Keeping improving. So overall, our business in a very healthy place, with a few places where we need to work on as mentioned, so Europe And paper, but to the point of Europe, I'd like to mention as well that margin improvement has been great. So Volume challenged in Europe, as we know, but okay, not great. And when I think about Our operating income, it almost doubled in Europe in the Q3.

Speaker 2

So the team has done some really good work.

Operator

Our next question is from the line of Andy Wittmann with Robert W. Baird. Please proceed with your questions.

Speaker 11

Great. Thanks for taking my questions, Hi, guys. I guess maybe Scott, probably for you.

Speaker 2

When I was just looking at the adjustments to

Speaker 11

the results, I noticed that there is $26,000,000 of restructuring And the total exclusions were $0.13 for the quarter. You talked about last quarter expectation of 5 And actually, the guidance for 4th quarter is pretax around $30,000,000 by my calculations or $0.09 I guess, could you just talk about what the restructuring actions were in the quarter and the quarter ahead? Maybe which segments, Geographies, and are these is it another restructuring program that you've taken in the past forming here? Or can you just maybe talk about some of the operational effects of what you've achieved and are trying to achieve?

Speaker 7

Yes. Certainly, Andy. Happy to do that. Thanks for the question. Yes.

Speaker 7

So if we look at Q3, the special charges restructuring was higher than we had guided to, but that's really due to the timing of The phasing of our combined savings program that we had announced earlier this year that's really focused to your question on where we focused on it. This is really targeted around institutional and health Care and as well as Europe, it started in the end of last year and then we added on to it earlier this year. And that's what really drove it, but really around the timing of it. Still expected as I think I've talked about in previous calls that about of that program, about 90% of those costs are going to be done by the end of next year. Okay.

Speaker 7

And so there will

Operator

be a little bit of

Speaker 7

a tail going into 2024. But really then if you look at that, as Christophe talked Before, we're seeing the benefits in healthcare from the program there, but we're also seeing great improvement in the institutional businesses, And that's where it was really focused. And then as we talked about at the end of last year, the actions taken against Europe and Christophe mentioned that we're seeing really great margin Improvement in Europe as well. So I think the actions that

Speaker 2

we were taking are having the benefits we expected. Let me add a few comments here. So you totally Support what Scott just said. Obviously, I'm really happy that most of the combined programs are coming to a close By the end of this year, which was the plan, so delivered as expected as well. At the same time, we know that digital Artificial Intelligence will open some new productivity opportunities.

Speaker 2

So for us in the future, there's nothing Clear, in our plans right now, but we will keep looking at that. And if there is an opportunity to improve Significantly, our productivity through technology, in the quarters and years to come, we will certainly capture them and discuss that with you.

Operator

Our next question is from the line of Steve Byrne with Bank of America. Please proceed with your question.

Speaker 7

Yes. Thank you. Christophe, I'd like to hear your view or maybe ranking among your 4 Key product areas, water, hygiene, energy and pest with respect to potential share gains. And would you expect your SG and A to increase over time commensurate with revenue growth? Or Do you see a pathway to perhaps reduce that 47,000 headcount in a way that Either utilize your digital approach or whatever to be more efficient and help you reach that 20% operating margin goal.

Speaker 7

Yes, maybe two questions in your question here, Steve. So first, in terms of share gain, We

Speaker 2

know the consumer good companies, so it's a bit harder to have the exact numbers, obviously here. But directionally, When I look at the big ones, so I and S, up 12% in a flat market. So that's Obviously indicating so very interesting share gains. First elimination, up double digit when competition is Either in the single digit or down, for some of them as well. Well, that's showing as well as so share gain.

Speaker 2

Industrial, even comparing to a very strong last You're in the mid single, well PMI in the U. S. And in the EU is negative. So that's also showing And as mentioned, so in healthcare, so growing back again, is also showing so quite a healthy performance. So overall, I like a lot of how we're progressing versus our peers in the marketplace.

Speaker 2

Now to your question on SG G and A, as I've shared with you, so in the past, I think that ultimately the company is going to be much bigger in the years to come. I don't think that our team is going to be much bigger, but I'm not expecting the team so to be reduced, But it might be in different places and I want to make sure that the number one place where I want to have All the firepower I can is in the frontline, which means our team serving our customers We will leverage digital and AI technology, not only to improve productivity, to help them Serve more customers, sell more solutions, but more importantly, spend way more time in creating value for our customers, which drives obviously saw value for our customers, which drives new business, which drives pricing and ultimately saw, improves our margin. So the way I think about SG and A in ratio, it's going to keep going down, the years to come. But ultimately, I'll make sure as well that through digital technology, we increase the impact of our frontline with our customers, which has been core to this company for the years past 2.

Operator

Thank you. Our next question is from the line of Patrick Cunningham with Citi. Please proceed with your question.

Speaker 3

Hi, good afternoon. On the Life Sciences business, How should we think about new business growth and investment into next year given some of the persistent near term weakness sort of juxtaposed with The long term growth opportunity and margin expansion that you highlighted in your Investor Day.

Speaker 2

Yes. So Patrick, so on life science, we've seen some improvement, which is good, in the Q3 in a market that's generally Down. And I see that so as a short term impact in the industry, It's an industry, so pharma, biotech, that is very promising. So for the future, a few challenging times, for a Few quarters, we'll see how many more quarters that's going to last for the industry out there. But I'm very bullish, with where the industry As a whole, it's going in the years to come.

Speaker 2

Now when it comes to our own performance, well, the fact that we have Positive growth is also a sign of the new business that we're generating, The share that we're gaining as well so versus our competition. And it's in that time that Ecolab usually focuses the Most in investing so for the future. And as I've shared, during Investor Day, well, we're investing in capacity, Making sure that we will have enough production capacity, so for the years to come to deliver our growth and not just in one location, But in several locations in Asia, in Europe, and in North America. And at the same time, it's also building capabilities, it's Building our team, it's building expertise, it's building science and R and D as well at the same time. And If the market is a bit different short term than what we had expected a year or 2 ago, our investment plan haven't changed Because for me, the future is totally unchanged.

Speaker 2

It's just a short term impact, that the market is having, on everyone's performance.

Operator

The next question is from the line of Kevin McCarthy with Vertical Research Partners. Please proceed with your question.

Speaker 7

Yes. Good afternoon. Christophe, I'd welcome your updated thoughts on the Healthcare business. I guess in terms of operations, would you expect that business to grow on par with your corporate average next year or Better or worse? And then on the strategic side, I think you've now separated infection prevention from surgical and maybe you can Kind of talk through what you're seeing in terms of incremental benefits from that in the early days as it relates Customer touches and productivity and the like.

Speaker 2

Yes. Thank you, Kevin. So three things. First is bifurcation, infection prevention and surgical as mentioned earlier, is progressing very well. It's really providing the right focus for the surgical business that's serving different people in a hospital than infection prevention, which is much closer To institutional, this is helping, obviously, so the surgical business.

Speaker 2

And the fact that infection prevention is Now, so, managed by the institutional team, well, we get not only so the reach because they serve way more hospitals For institutional products, obviously, than Healthcare did, well, you get immediate synergies from a growth perspective. You get the synergies on the cost side as well because it's a way bigger team than what healthcare as well used to be. So in terms of transformation, I like the Progress that's being made. Now, in terms of growth performance, if I think short term speak 24. I think healthcare is going to be below average of the company and more longer term.

Speaker 2

Well, my objective is to make sure Our healthcare business becomes at least at the average of the company, if not better, but that's going to take some time and some work in order to get there.

Operator

Our next question comes from the line of Vincent Andrews with Morgan Stanley. Please proceed with your question.

Speaker 3

Thank you and good afternoon everyone. Just a question from me on inventories. Just looking at it, it's down Mid high teens year over year, but your volume is kind of flattish and price is up on your delivered products. So I'm just trying to understand, The frauds are still sort of flattish. What's helping the inventory come down and improve the working capital performance?

Speaker 2

Thank you, Vincent. I'm going to pass this one to Scott.

Speaker 7

Thanks, Vincent. I'd be happy to answer this. So, yes, as you probably saw, our Q3 working capital was about $250,000,000 favorable versus last year And largely driven by some targeted inventory reductions. We're down DOH is down about 10 days, so the rate impact on that versus the end of last year. So That's really been driven by as the supply chain team has driven great supply chain resilience and allowed us to go after and reduce those inventory levels.

Speaker 7

And so I would expect Really like the working capital trajectory and expect really strong free cash flow growth through the balance of the year and Frankly, expect our free cash flow conversion to be above historical levels, which tends to be mid-90s and expect that free cash flow conversion to be

Operator

Our next question is from the line of Rosemarie Morbelli of Gabelli Funds. Please proceed with your question.

Speaker 12

Thank you.

Speaker 2

Congratulations,

Speaker 12

everyone, On that great quarter, institution did really quite well. And I was in Well, I was in several hotels recently, and the level of cleaning, changing sheets, changing towels and so on Has come down substantially. I know you are adjusting your operations to reflect this different world. But I was wondering if you could give us a little more details on what you are doing, because if they don't change anything, You obviously don't sell your products, services and so on. Details would be appreciated.

Speaker 12

Thanks.

Speaker 2

Thank you, Rosemarie. This is a core element of focus between us and our hospitality Customers, it was initially driven by shortage, obviously, of labor That they didn't have to do all that work, which is still a challenge for that industry. At the same time, Well, they like the fact that less labor meant as well less cost while pricing saw When up, that drove good margins, for institutional customers, which ultimately is a good thing for the industry. And when the industry is doing well, it's a good thing for us as well at the same time. That being said, quality standards need to get back To where they used to be, it's exactly playing into what we're doing, which is having products That are delivering better quality, better standards, better cleanliness with less labor.

Speaker 2

So it's 2 in 1, 3 in 1, it's automated dish machine, laundry, floor cleaning, whatever those Solutions might be as well, so for the industry. So we've reoriented really over the last 2 years all our innovation towards Increasing even more the automation level for our customers in order to drive better cleanliness while using less labor and keeping the margins that they used to have. So at the end of the day, if our institutional industry hadn't changed for A long time, like 100 years, I think that the past few years, it's an industry that has made a step change in terms of lead bridging technology More than ever, while this is exactly what we're doing, for me, it's going to help bring, our partnership Between us and our customers to a whole new level, helping them perform better and for us leveraging all the innovations that we have to offer. So At the end of today, a good news and cleanliness is going to improve as well, in the hotels that you're going to visit.

Operator

Thank you. The next question is from the line of Scott Schneeberger, Oppenheimer. Please proceed with

Speaker 1

your question.

Speaker 2

Thanks very much. Christophe, could

Speaker 3

you give us an update? It's been, I think, nearly 5 years since data centers and animal health became big areas of focus at the company. Could you speak to growth rates at both and how meaningful they've become within their sub segments of industrial? Thanks.

Speaker 2

Well, the 2 are very different, obviously. So data centers is growing At incredible rates. We're not giving sort of the detail here, but It's strong and it keeps accelerating. So it's north of 30%, so which is quite remarkable. You see that with the high-tech companies, obviously, saw the usage of cloud is going up exponentially.

Speaker 2

They need way more computing power in places where there is limited water as well at the same time. And there's almost no one out there who can Serve them in a way that's increasing capacity, reducing water consumption and at the same time, making sure that, the up Time remains close to 100%. So quite a challenge from a technology and expertise perspective. This is playing exactly To our strength as a company, that's why having focused on that business, having a dedicated team on it is paying off more than ever. And I think that we are at the beginning, of that growth journey, which is really good.

Speaker 2

Animal Health, a total different story, obviously, since the The promise there is as the food industry is moving away, at least in places where it's still being used antibiotics, Well, you need to have much higher level of hygiene in the farms that are growing, obviously, so these animals. We've been building that over the last few years. It's not an exponential growth like data centers Has been, is and even more will be in the future, but that's a business that's in a good place, but that you can't compare with the data center business, but it's a very good complement to our food and beverage business, which Is doing really well, overall. So I like those focus and investments that we're making, in those industries, but they're very different from each other.

Operator

Thank you. Our next question is from the line of Josh Spector with UBS. Please proceed with your question.

Speaker 5

Yes. Hi. Thanks for taking my follow-up. I guess, 2 quick ones, probably both for Scott is, when I look at SG and A, so flat into 4th Quarter, if I think about normal seasonality and what that means for next year, extrapolating that gets me to like $4,400,000,000 to $4,500,000,000 or another 10% increase. I guess, is that the right way to think about it?

Speaker 5

Or would you expect it to move differently than that? And just second, you have about $1,000,000,000 plus in debt due in the next Quarter is pretty low coupon. Are you looking to pay that off or would you roll that? Thanks.

Speaker 7

Yes, Josh. I'll handle the 2 follow ups. The first one on the debt and where we sit today, have strong liquidity as you saw on the free cash flows for The Q3 and the expectation for the full year, and we ended, the Q3 with around about $1,000,000,000 of cash. So expectation there, again, long term focus on capital allocation remains the same, but obviously in the short term, we're very committed to deleveraging And on a good path to do that. At the end of the Q3, leverage ratio was about 2.5 and feel very good by the end of next year to get back down to our historical sort of 2 times range.

Speaker 7

Getting back to your SG and A question. As we talked about and Christophe talked about in the open, the Q3 dollar was what we I expect similar levels in Q4 as you talked about, but the year over year really largely driven by this incentive compensation. And so And then as well, if you look at Q3, had a tougher comp, low incentive compensation last year, but that underlying productivity remains really strong. Just for perspective on that, the SG and A, as Christophe talked about, we will continue to grow this business, but we're needing less people. And actually, in the Q3, our headcount year over year was down on SG and A 2%.

Speaker 7

And so our sales per head was up about 7%. So showing that good productivity. I would expect it's early to sort of talk about 2024, but we'll expect to continue to drive great productivity next year, leveraging the technology that we've continued to deploy and really increasing the time that our sales team spent on creating customer value.

Speaker 2

Maybe two points to build on what you just Said, Scott. On SG and A, it's 100% under our control. We've demonstrated for years that we drive Productivity the right way. It's not by squeezing cost. It's by automating our operations and focusing our teams on creating value with our customers.

Speaker 2

So I completely expect that in the years to come through technology, through digital, through AI, We will keep on that journey and feel really confident about that. And the point on cash flow and debt speak balance sheet. For me, in those times, having a very strong balance sheet, not only has been true for us for many, many years, it's especially true Today, so getting our working capital, so as tight as it can be, getting our cash flow as strong as it can be through volume, new business, Pricing and all that business, obviously, so generated is absolutely essential. So on the two sides, I keep Looking for good progression both on SG and A productivity and the strengthening of the balance sheet.

Operator

Thank you. Mr. Hedberg, there are no further questions at this time. I'd like to turn the floor back over to you for closing remarks.

Speaker 1

Thank you. That wraps up our 3rd quarter conference call. This conference call and the associated discussion slides will be available for replay on our website. Thank you for your time and participation. Hope everyone has a great rest of your day.

Operator

Thank you. Ladies and gentlemen, thank you for your participation. This does conclude today's teleconference. And you may now disconnect your lines and have a wonderful day.

Powered by Quartr

Key Takeaways

  • Ecolab reported 7% organic sales growth and 18% adjusted EPS growth in Q3, hitting the high end of its guidance.
  • Value-based pricing (+7%) and new business wins drove accelerating volumes that helped offset softer global end-market demand.
  • Margins expanded notably, with organic operating income margin up 160 basis points to 15.5% and adjusted gross margin up 360 basis points to 41.3%.
  • Institutional & Specialty grew organic sales double-digits and organic operating income 28%, while Industrial continued share gains in food & beverage and water solutions.
  • For Q4, Ecolab expects 17%–24% adjusted EPS growth—pushing full-year EPS above $19—and sees mid-teens EPS growth in 2024 toward its long-term margin goals.
AI Generated. May Contain Errors.
Earnings Conference Call
Ecolab Q3 2023
00:00 / 00:00